Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to assess real life tolerance and Lenvatinib plasma exposure after dose reduction in Thyroid Cancer Patients

Trial Profile

Study to assess real life tolerance and Lenvatinib plasma exposure after dose reduction in Thyroid Cancer Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2018 New trial record
    • 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top